Shopping Cart
Remove All
Your shopping cart is currently empty
Gypenoside LI is a natural product with anticancer activity that generates ROS, downregulates procaspase-8 and MMP-2/9, inhibits Wnt/β-catenin signaling, and induces cell cycle arrest and apoptosis.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $98 | - | In Stock | |
| 5 mg | $263 | - | In Stock | |
| 10 mg | $428 | - | In Stock | |
| 25 mg | $698 | - | In Stock |
| Description | Gypenoside LI is a natural product with anticancer activity that generates ROS, downregulates procaspase-8 and MMP-2/9, inhibits Wnt/β-catenin signaling, and induces cell cycle arrest and apoptosis. |
| In vitro | Gypenoside LI (0-80 μM) dose-dependently inhibited the activity of A549 cells, inducing G2/M phase cell cycle arrest and apoptosis in these cells [1]. Gypenoside LI (75 and 29.71 μg/mL) could induce endogenous apoptosis in cells, accompanied by S-phase cell cycle arrest. Gypenoside LI reduced the colony-forming ability of melanoma cells by inhibiting the Wnt/β-catenin signaling pathway [2]. |
| Molecular Weight | 801.02 |
| Formula | C42H72O14 |
| Cas No. | 94987-10-7 |
| Smiles | C[C@]12[C@@]3(C)[C@@]([C@@]([C@](CCC=C(C)C)(C)O)(CC3)[H])([C@H](O)C[C@@]1([C@]4(C)[C@@](CC2)(C(C)(C)[C@@H](O[C@H]5[C@H](O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@@H](O)[C@H](O)[C@@H](CO)O5)[C@H](O)C4)[H])[H])[H] |
| Relative Density. | 1.33 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80.00 mg/mL (99.87 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.